
ROCKVILLE, Md., May 03, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical ...

Study met its primary endpoint with TG-1101 (ublituximab) plus ibrutinib increasing Overall Response Rate ...

PRESS RELEASE - Friday, 7 October 2016, 07:00 CEST THREE IDYLLA(TM) TEST PERFORMANCE STUDIES TO ...
Click to continue to site. Closing